Johannes SmitEndocrineSmit J. Tyrosine kinase inhibitors in thyroid cancer. Endocr Abstracts. 2010;22. Abstract S5.3.Smit J. Tyrosine kinase inhibitors in thyroid cancer . Endocr Abstracts . 2010;22. Abstract S5.3.
深入研究「Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials」主題。共同形成了獨特的指紋。 Randomized Controlled Trial Pharmacology, Toxicology and Pharmaceutical Science 100% Thyroid Cancer Pharmacology, Toxicology and Pharmaceutical...
This review will focus on the use of tyrosine kinase inhibitors (TKIs) in thyroid cancers and a summary of the results of clinical trials to date will be presented. 展开 收藏 引用 批量引用 报错 分享 全部来源 求助全文 ibrarian.net 相似文献 参考文献...
AbbaspourBabaei M, Kamalidehghan B, Saleem M, Huri HZ, Ahmadipour F (2016) Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Dev Ther 10:2443–2459 ArticleGoogle Scholar Brizzi MF, Zini MG, Aronica MG, Blechman JM, Yarden Y, Pegoraro ...
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then bl
Shawver LK, Slamon D, Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002, 1: 117-123. 10.1016/S1535-6108(02)00039-9 CAS PubMed Google Scholar Hubbard SR: Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr Opin Struct Biol. 2002...
Renal Cell Cancer SimonChowdhuryMA, MRCP, PhD, ...Nizar M.TannirMD, inHematology/Oncology Clinics of North America, 2011 Tyrosine Kinase Inhibitors Kinase inhibitorsare drugs that generally inhibittyrosine kinase(TK) enzymes, which catalyze the transfer of phosphate groups from adenosine triphosphate ...
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then bl
tyrosine hydroxylase inhibitors Tyrosine Hydroxylase-Immunoreactive Tyrosine Hydroxylase-Like Immunopositive Tyrosine Hydroxylase-Like Immunoreactive tyrosine iodinase Tyrosine kinase Tyrosine kinase Tyrosine kinase Tyrosine kinase Tyrosine kinase 2 tyrosine kinase 2 deficiency ...
RET is a well-defined clinical target in thyroid cancer, as recently demonstrated by XL184 and ZD6474, two multikinase inhibitors that are approved for the treatment of advanced MTC[34-37]. Although AL3810 inhibits RET kinase activity at submicromolar concentrations in enzymatic assays, the high ...